Table 3

Results of multivariable analysis for unresponsiveness to IVIG

Regression analysisP valueP valuePropensity score analysisP valueP value
UnadjustedAdjustedMatchingIPTW
Risk ratio (95% CI)Risk ratio (95% CI)Risk ratio (95% CI)Risk ratio (95% CI)
HD(Reference)(Reference)(Reference)(Reference)
Non-HD1.04 (0.92 to 1.19)0.501.09 (0.92 to 1.29)0.301.08 (0.81 to 1.45)0.601.09 (0.94 to 0.26)0.25
Age (year)1.03 (0.97 to 1.08)0.31
Male1.22 (1.08 to 1.38)<0.001
Clinical day of IVIG0.83 (0.74 to 0.94)0.002
Serum Na (mEq/L)0.94 (0.91 to 0.98)<0.001
AST (IU/L)1.00 (1.00 to 1.00)<0.001
% of Neutrophil1.02 (1.01 to 1.03)0.001
Platelet count (109/L)1.00 (1.00 to 1.00)<0.001
C reactive protein (mg/dL)1.02 (1.01 to 1.03)<0.001
  • Additionally, online supplemental tables S2 an S3 summarise the results of the multivariable analysis for the risk of developing CALs and unresponsiveness to the initial IVIG treatment based on the use of low-dose ASA within the non-HD group.

  • ASA, acetylsalicylic acid; AST, aspartate aminotransferase; CALs, coronary artery lesions; HD, high dose; IPTW, inverse probability of treatment weighting; IVIG, intravenous immunoglobulin.